Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12396169 | 0.95 | CCR3 (0.43) | OPRD1EPHX1OPRM1HTR1ADRD4 | |
| SCHEMBL12396167 | 0.94 | CCR3 (0.44) | OPRD1EPHX1OPRM1HTR2ACCR3 | |
| SCHEMBL12396192 | 0.93 | CCR3 (0.45) | OPRD1OPRM1HTR2ACCR3MCHR1 | |
| SCHEMBL12396159 | 0.90 | RAB9A (0.51) | EPHX1DRD4DRD3CCR3MCHR1 | |
| SCHEMBL12396172 | 0.86 | CCR3 (0.48) | CCR3MCHR1RAB9ASMN1; SMN2 | |
| SCHEMBL12396173 | 0.85 | CCR3 (0.48) | HTR2ACCR3MCHR1 | |
| SCHEMBL12396174 | 0.85 | CYP1A2 (0.44) | OPRM1CCR3MCHR1SMN1; SMN2 | |
| SCHEMBL12396178 | 0.85 | EPHX1 (0.44) | EPHX1OPRM1HTR2ACCR3MCHR1 | |
| SCHEMBL12396138 | 0.84 | CCR3 (0.44) | OPRD1OPRM1HTR2ACCR3RAB9A | |
| SCHEMBL12396176 | 0.83 | CYP1A2 (0.40) | OPRM1HTR2ACCR3MCHR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183358-A1 | METHODS AND COMPOSITIONS FOR DEREPRESSION OF IAP-INHIBITED CASPASE | THE BURNHAM INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2009-02-12 | — | — | US | disclosed |
| US-7217688-B2 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217688-B2 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | OPRD1 4625/4885EPHX1 3115/4885OPRM1 4782/4885 |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | OPRD1 4625/4885EPHX1 3115/4885OPRM1 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.